Expression of p21 (waf1/cip1/sdi1), but not p53 protein, is a factor in the survival of patients with advanced gastric carcinoma

Cancer

Volumn 79, Issue 11, 1997, Pages 2067-2072

  Gomyo, Yoshihito ^a   Ikeda, Mitsuyuki ^a   Osaki, Mitsuhiko ^a   Tatebe, Shigeru ^a   Tsujitani, Shunichi ^a   Ikeguchi, Masahide ^a   Kaibara, Nobuaki ^a   Ito, Hisao ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

gastric carcinoma; immunohistochemistry; p21; p53; prognosis

Indexed keywords

PROTEIN P21; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STOMACH CARCINOMA; SURVIVAL RATE; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031009467     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970601)79:11<2067::AID-CNCR3>3.0.CO;2-M     Document Type: Article

References (38)

1. Finlay CA, Hinds PW, Levine AJ. The p53 protooncogene can act as a suppressor of transformation. Cell 1989;57:1083-93.
2. El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994;54:1169-74.
3. Sheikh MS, Rochefort H, Garcia M. Overexpression of p21waf1/cip1 induces growth arrest, giant cell formation and apoptosis in human breast carcinoma cell lines. Oncogens 1995;11:1899-905.
4. Zhan Q, Bae I, Kastan MB, Fornace AF Jr. The p53-dependent gamma-ray response of GADD45. Cancer Res 1994; 54:2755-60.
5. Zhan Q, Fan S, Bae I, Guillouf C, Liebermann DA, O'Connor PM, et al. Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene 1994;9:3743-51.
6. Lane DP. p53, guardian of the genome. Nature 1992;358:15-6.
7. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 1988;8:531-9.
8. Lane D, Benchimol S. p53: oncogene or anti-oncogene. Genes Dev 1990;4:1-8.
9. Oiwa H, Maehara Y, Ohno S, Sakaguchi Y, Ichiyoshi Y, Sugimachi K. Growth pattern and p53 overexpression in patients with early gastric cancer. Cancer 1995;75:1454-9.
10. Starzynska T, Blomley M, Ghosh A, Stern PL. Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br J Cancer 1992;66:558-62.
11. Martin HM, Filipe MI, Morris RW, Lane DP, Silvestre F. p53 expression and prognosis in gastric carcinoma. Int J Cancer 1992;50:859-62.
12. Hurlimann J, Saraga EP. Expression of p53 protein in gastric carcinomas. Am J Surg Pathol 1994;18:1247-53.
13. Joypaul BV, Hopwood D, Newman EL, Qureshi S, Grant A, Ogston SA, et al. The prognostic significance of the accumulation of p53 tumour-suppresser gene protein in gastric adenocarcinoma. Br J Cancer 1994;69:943-6.
14. Zeng ZS, Sarkis AS, Zhang ZF, Klimstra DS, Charytonowicz E, Guillem JG, et al. p53 nuclear overexpression: an independent predictor of survival in lymph node-positive colorectal: cancer patients. J Clin Oncol 1994;12:2043-50.
15. Sarbia M, Porschen R, Borchard F, Horstmann O, Willers R, Gabbert HE. p53 protein expression and prognosis in squamous cell carcinoma of the esophagus. Cancer 1994; 74:2218-23.
16. Ebina M, Steinberg SM, Mulshine JL, Linnoila I. Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res 1994;54:2496-503.
17. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 1994;54:3391-5.
18. Bond JA, Blaydes JP, Rowson J, Haughton MF, Smith JR, Wynford TD, et al. Mutant p53 rescues human diploid cells from senescence without inhibiting the induction of SDI1/ WAF1. Cancer Res 1995;55:2404-9.
19. Barboule N, Mazars P, Baldin V, Vidai S, Jozan S, Martel P, et al. Expression of p21WAF1/CIP1 is heterogeneous and unrelated to proliferation index in human ovarian carcinoma. Int J Cancer 1995;63:611-5.
20. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-dase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981;29:577-80.
21. Kawai K, Serizawa A, Hamana T, Tsutsumi Y. Heat-induced antigen retrieval of proliferating cell nuclear antigen and p53 protein in formalin-fixed, paraffin-embedded sections. Pathol Int 1994;44:759-64.
22. Oohashi Y, Watanabe H, Ajioka Y, Hatakeyama K. p53 immunostaining distinguishes malignant from benign lesions of gallbladder. Pathol Int 1995;45:58-65.
23. Bass IO, Mulder JWR, Offerhaus GJA, Vogelstein B, Hamilton SR. Immunohistochemistry of altered p53 supressor gene product in colorectal neoplasms [abstract]. Lab Invest 1993;68:234.
24. Gomyo Y, Osaki M, Kaibara N, Ito H. Numerical aberration and point mutation of p53 gene in human gastric intestinal metaplasia and well-differentiated adenocarcinoma: analysis by fluorescence in situ hybridization (FISH) and PCR-SSCP. Int J Cancer 1996;66:594-9.
25. Van den Berg FM, Baas IP, Polak M, Offerhaus GJ. Detection of p53 overexpression in routinely paraffin embedded tissue of human carcinomas using a novel target unmasking fluid (TUF). Am J Pathol 1993;142:381-5.
26. Bartek J, Iggo R, Gannon J, Lane DP. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 1990;5:893-9.
27. Iggo R, Gatter K, Bartek J, Lane DP, Harris AL. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990;335:675-9.
28. Tamura G, Kihana T, Nomura K, Terada M, Sugimura T, Hirohashi S. Detection of frequent p53 gene mutations in primary gastric cancer by cell sorting and polymerase chain reaction single-strand conformation polymorphism analysis. Cancer Res 1991;51:3056-8.
29. ras-generated signals towards cell growth or apoptosis is determined by protein kinase C and Bcl-2. Oncogene 1995;11:1487-98.
30. Cip1. Oncogene 1995;11:1675-83.
31. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF-1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
32. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21-cdk-interacting protein cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805-16.
33. Shiohara M, EL-Deiry WS, Wada M, Nakamaki T, Takeuchi S, Yang R, et al. Absence of WAF1 mutations in a variety of human malignancies. Blood 1994;84:3781-4.
34. WAF1/CipI in human brain tumors. Oncogene 1995;11:2021-8.
35. WAF1 and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up. Clin Cancer Res 1996;2:1591-9.
36. Johnson EA, Davidson AG, Hostetter RB, Cook LL, Thomas EM, Quinlan DC. The expression of Waf-1 in node-negative infiltrating ductal breast carcinoma. Proc Am Assoc Cancer Res 1996;37:569.
37. Khaoustov VI, Ozer A, Smith JR, Noda A, Mearns M, Krishnan B, et al. Induction of senescent cell-derived inhibitor of DNA synthesis gene, SDI1, in hepatoblastoma (HepG2) cells arrested in the G2-phase of the cell cycle by 9-nitrocamptothecin. Lab Invest 1995;73:118-2.
38. DiGiuseppe JA, Redston MS, Yeo CJ, Kern SE, Hruban RH. p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. Am J Pathol 1995;147:884-8.